Acadia Pharmaceuticals (ACAD) EBT (2010 - 2026)

Acadia Pharmaceuticals' EBT history runs 17 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• On a quarterly basis, EBT fell 85.68% year-over-year to $4.0 million in Q1 2026; TTM through Mar 2026 was $115.1 million, a 56.55% decrease from a year earlier, with the FY2025 full-year figure at $138.9 million, down 46.18% from the prior year.
• EBT declined to $4.0 million in Q1 2026 per ACAD's latest filing, from $26.3 million in the prior quarter.
• Across five years, EBT topped out at $161.1 million in Q4 2024 and bottomed at -$112.6 million in Q1 2022.
• The 5-year median for EBT is $21.0 million (2024), against an average of $8.0 million.
• Across the five-year window, EBT tumbled 97.35% in 2023 and jumped 486.19% in 2024, its largest moves.
• Year by year, EBT stood at -$40.8 million in 2022, then jumped by 197.11% to $39.7 million in 2023, then jumped by 306.1% to $161.1 million in 2024, then sank by 83.67% to $26.3 million in 2025, then plunged by 84.87% to $4.0 million in 2026.
• Per Business Quant, the three latest ACAD EBT figures stand at $4.0 million (Q1 2026), $26.3 million (Q4 2025), and $44.6 million (Q3 2025).